Evogene Surges to 423rd in Trading Volume with 742819.19% Spike Amid Generative AI Breakthrough

On June 10, 2025, Evogene (EVGN) experienced a significant surge in trading volume, reaching 240 million, marking a 742819.19% increase from the previous day. This substantial rise placed Evogene at the 423rd position in terms of trading volume for the day. The stock price of Evogene also saw a remarkable increase of 100.00%, continuing its upward trend for the second consecutive day, with a total gain of 105.45% over the past two days.

Evogene has made a significant breakthrough with the completion of its generative AI foundation model, version 1.0, specifically designed for small molecule discovery and optimization. This model, developed in collaboration with Google Cloud, represents a major advancement in the company's capabilities. The new model is built on a vast dataset of approximately 38 billion molecular structures and is trained and deployed using Google Cloud's advanced AI infrastructure, including high-performance GPUs and scalable storage.

The generative AI foundation model addresses a critical challenge in the pharmaceutical and agricultural industries: identifying novel small molecules that meet multiple product criteria. Unlike traditional discovery methods, this model supports the simultaneous consideration of multiple complex product requirements while creating novel molecular structures. This approach not only enhances the discovery process but also facilitates the development of strong, defensible intellectual property portfolios.

Internal computational tests have shown that the new model achieves approximately 90% precision in designing novel molecules, a significant improvement over the 29% accuracy of conventional AI models. This precision is crucial for overcoming long-standing challenges in life-science R&D, such as reducing late-stage failure in pharmaceuticals and developing effective, sustainable, and proprietary agricultural chemicals.

Ofer Haviv, President and CEO of Evogene, highlighted the significance of this milestone, stating that the completion of the foundation model unlocks new frontiers for ChemPass AI. This advancement gives Evogene the power to generate wholly novel molecules that not only perform well but also create new intellectual property space. The company is already working on version 2.0 of its generative AI foundation model, with a focus on enhanced flexibility for multi-parameter optimization.